stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Return on invested capital
Halozyme Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 19.9%, up 5.6 percentage points from fiscal 2025 (14.3%). Over the past ten years it has ranged from −208.9% (fiscal 2018) to 51.8% (fiscal 2021); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 14.3% | (12.75) |
| FY2024 | 27.1% | 10.14 |
| FY2023 | 16.9% | 4.19 |
| FY2022 | 12.7% | (39.10) |
| FY2021 | 51.8% | 1.81 |
| FY2020 | 50.0% | 107.83 |
| FY2019 | −57.8% | 151.11 |
| FY2018 | −208.9% | (208.92) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| EXEL Exelixis, Inc. compare | 66.6% |
| HALO Halozyme Therapeutics, Inc. | 19.9% |
| ASND Ascendis Pharma A/S compare | 15.1% |
| TECH Bio-Techne Corp compare | 7.70% |
| JAZZ Jazz Pharmaceuticals PLC compare | 3.86% |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.73% |
| BBIO BridgeBio Pharma, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| KYMR Kymera Therapeutics, Inc. compare | −39.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement